Supporting the Arginase-1 Deficiency Community
Diagnosing
Arginase 1 Deficiency (ARG1-D) is a rare genetic disorder that can be difficult to recognize. Learn about symptoms, testing, and the diagnostic journey for individuals and families affected by ARG1-D.
Treatment
Treatment for ARG1-D focuses on managing arginine levels, reducing symptoms, and improving quality of life. Explore current treatment options, dietary management, and emerging therapies.
Welcome
Welcome to the patient advocacy website for support and information regarding Arginase 1 Deficiency (ARG1-D). We are glad you found us. Our community is made up of parents, family members, friends and caregivers who have also faced this diagnosis and understand the range of emotions and questions you may have. We are here to provide information on ARG1-D, resources to guide you on this journey and perhaps most importantly, we are here to let you know that you are not alone. We hope you find this website a valuable resource as you learn more about ARG1-D, and that you reach out to us should you have additional questions or needs.
Arginase 1 Deficiency News
International ARG1-D Day – June 10, 2026
Today, on International Arginase 1 Deficiency (ARG1-D) Day, we join families, patients, clinicians, researchers, and advocates around the world to raise awareness of this ultra-rare
In Honor of JOSH on RARE DISEASE DAY
A Mother’s Story Joshua Eaton, Pioneer in the ARG1-D Community, Age 27 South Shore, Massachusetts We share Josh’s story so his life can inspire others
Historic News For The Arg1-d Community
Yesterday, the U.S. Food and Drug Administration (FDA) approved Pegzilarginase (Loargys) — the first and only treatment for Arginase 1 Deficiency (ARG1-D). This is not
Supporters
Through this partnership, NUCDF and the ARG1-D Foundation work together to advance awareness, education, research, and access to resources. By aligning our efforts, we can better support families, strengthen community connections, and help drive progress toward improved care, treatments, and outcomes for those impacted by ARG1-D.